Episurf — Share Issue/Capital Change 2025

Mar 31, 2025

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B): During the period 10 February 2025 up to and including 24 February 2025, shareholders exercised 1,586,850 warrants (TO13B). The number of shares has increased by 1,586,850 B-shares, and the number of votes has increased by 1,586,850. The remaining warrants (TO13B) have expired.

The total number of shares amounts to 653,064,692, where 473,357 are A-shares, and 652,591,335 are B-shares. The total number of votes after the conversions amounts to 654,011,406.

For more information, please contact:

Veronica Wallin, CFO, Episurf Medical Tel:+46 (0) 700 37 48 95 Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be costefficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CEST on 31 March 2025.